TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.4% Following Insider Selling


Share on StockTwits

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price dropped 4.4% during trading on Thursday following insider selling activity. The company traded as low as $31.53 and last traded at $32.03. Approximately 4,154 shares were traded during trading, a decline of 100% from the average daily volume of 835,500 shares. The stock had previously closed at $33.50.

Specifically, VP John F. Sullivan sold 9,617 shares of the business’s stock in a transaction that occurred on Tuesday, January 19th. The stock was sold at an average price of $22.12, for a total value of $212,728.04. Following the completion of the sale, the vice president now owns 20,445 shares in the company, valued at $452,243.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John F. Carey sold 3,360 shares of the stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $36.87, for a total value of $123,883.20. Following the sale, the vice president now directly owns 3,360 shares of the company’s stock, valued at approximately $123,883.20. The disclosure for this sale can be found here. Insiders have sold 288,435 shares of company stock worth $9,234,573 over the last three months. Insiders own 13.10% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Cowen raised their price target on shares of TransMedics Group from $44.00 to $49.00 and gave the stock an “outperform” rating in a report on Monday, March 29th. Canaccord Genuity increased their price objective on TransMedics Group from $46.00 to $79.00 and gave the stock a “buy” rating in a report on Monday, March 15th. Oppenheimer boosted their target price on TransMedics Group from $25.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, March 2nd. Zacks Investment Research upgraded shares of TransMedics Group from a “sell” rating to a “hold” rating in a report on Saturday, April 3rd. Finally, Morgan Stanley upped their price objective on shares of TransMedics Group from $16.00 to $38.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 9th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. TransMedics Group presently has a consensus rating of “Buy” and a consensus price target of $41.00.

The company has a quick ratio of 10.36, a current ratio of 11.31 and a debt-to-equity ratio of 0.32. The company has a fifty day simple moving average of $37.97 and a 200 day simple moving average of $22.38. The firm has a market capitalization of $897.46 million, a P/E ratio of -23.93 and a beta of 2.16.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, March 1st. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. TransMedics Group had a negative return on equity of 38.95% and a negative net margin of 131.35%. As a group, equities analysts expect that TransMedics Group, Inc. will post -1.18 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of TMDX. California Public Employees Retirement System grew its holdings in shares of TransMedics Group by 30.5% during the third quarter. California Public Employees Retirement System now owns 52,200 shares of the company’s stock valued at $719,000 after buying an additional 12,200 shares during the last quarter. BlackRock Inc. raised its holdings in TransMedics Group by 19.6% in the 3rd quarter. BlackRock Inc. now owns 1,567,596 shares of the company’s stock worth $21,602,000 after acquiring an additional 257,082 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in TransMedics Group by 12.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 13,838 shares of the company’s stock valued at $191,000 after acquiring an additional 1,546 shares in the last quarter. State Street Corp boosted its stake in TransMedics Group by 8.7% during the 3rd quarter. State Street Corp now owns 338,228 shares of the company’s stock valued at $4,661,000 after purchasing an additional 27,133 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of TransMedics Group by 120.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,471 shares of the company’s stock worth $2,212,000 after purchasing an additional 87,548 shares in the last quarter. 76.68% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group (NASDAQ:TMDX)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Further Reading: What Are Treasury Bonds?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.